0.00Open0.00Pre Close0 Volume0 Open Interest1.50Strike Price0.00Turnover0.00%IV77.91%PremiumNov 8, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma135.80Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Altimmune Stock Discussion
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Benzinga· 1 min ago
In an MRI sub-study of 67 subjects from the Phase 2 MOMENTUM obesity trial, 50 of whom were treated with pemvidutide for 48 weeks, the lean loss ratio, defined as the change in lean mass compared to the change in total mass, was 21.9%.
Lean mass preservation was greater in subjects aged 60 years and older, in whom the ...
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
Altimmune presented results from a Phase 2 MRI-based body composition sub-study of pemvidutide at the 60th Annual Meeting of the European Association for the Study of Diabetes. The study, involving 67 subjects from the MOMENTUM obesity trial, showed promising outcomes for pemvidutide, a novel GLP-1/glucagon dual receptor...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
$Altimmune (ALT.US)$
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
No comment yet